Press release
Geron to Announce Fourth Quarter and Full-Year 2022 Financial Results on March 16, 2023
FOSTER CITY, Calif.--(BUSINESS WIRE)-- Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, today announced that it will
About this update from Geron Corporation
[{"type":"text","content":" FOSTER CITY, Calif.--(BUSINESS WIRE)--\nGeron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, today announced that it will release its fourth quarter and full-year 2022 financial results after the market closes on Thursday, March 16, 2023 via press release, which will be available on the Company’s website at www.geron.com/investors. Geron will host a conference call to discuss the financial results as well as upcoming milestones at 4:30 p.m. ET the same day.\n\nA live webcast of the conference call and related presentation will be available on the Company’s website at www.geron.com/investors/events. An archive of the webcast will be available on the Company’s website for 30 days.\n\nParticipants may access the webcast by registering online using the following link, https://conferencingportals.com/event/SmvlMvWL.\n\nAbout Geron\n\nGeron is a late-stage biopharmaceutical company pursuing therapies with the potential to extend and enrich the lives of patients living with hematologic malignancies. Its investigational first-in-class telomerase inhibitor, imetelstat, harnesses Nobel Prize winning science in a treatment that may alter the underlying course of these diseases. To learn more, visit http://www.geron.com/ or follow us on LinkedIn.\nView source version on businesswire.com: https://www.businesswire.com/news/home/20230309005285/en/\n\nAron Feingold\nInvestor and Media Relations\[email protected]\[email protected]\n\nSource: Geron Corporation","length":3964,"tagName":"div"}]